CareDx completes Naveris acquisition, adding cancer MRD testing
Tweet Send to a Friend
CareDx, Inc. (Nasdaq: CDNA) has completed its acquisition of Naveris, a deal first announced in April 2026, adding a blood-based ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


